Reverie Labs - About the company
Reverie Labs is an acquired company based in Boston (United States), founded in 2017 by Jonah Kallenbach and Ankit Gupta. It operates as a Provider of an AI based molecular modelling and optimization software for research & development. Reverie Labs has raised $32M in funding from Rough Draft Ventures and Ridgeback Capital Management. The company has 147 active competitors, including 64 funded and 10 that have exited. Its top competitors include companies like Recursion Pharmaceuticals, XtalPi and Schrodinger.
Company Details
Reverie Labs is a company focusing on accelerating the drug design pipeline. The company uses machine learning technology for lead generation and optimization. The company has developed structure-based predictive models for potency and ADME/PK properties of the small molecule. Additionally, the company also serves custom model requests.
- Website
- reverielabs.com
- Social
- Email ID
- *****@reverielabs.com
- Registered Address
- 678 Massachusetts Ave Cambridge, MA 02139
Key Metrics
Founded Year
2017
Location
Boston, United States
Stage
Acquired
Total Funding
$32M in 2 rounds
Latest Funding Round
Investors
Ranked
29th among 147 active competitors
Employee Count
27 as on Dec 31, 2022
Similar Companies
Exit Details
Acquired by Ginkgo Bioworks (Feb 28, 2024)
Legal entities associated with Reverie Labs
Reverie Labs is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
REVERIE LABS CIN: 821218564 , United States, Active | Dec 31, 1999 | - | 27 (As on Dec 31, 2022) | - |
Reverie Labs's acquisition details
Reverie Labs got acquired by Ginkgo Bioworks on Feb 28, 2024.
Click here to take a look at Reverie Labs's acquisition in detail
Sign up to download Reverie Labs' company profile
Reverie Labs's funding and investors
Reverie Labs has raised a total funding of $32M over 2 rounds. Its first funding round was on 2017. Its latest funding round was a Series A round on Feb 03, 2021 for $*****. 3 investors participated in its latest round. Reverie Labs has 16 institutional investors.
Here is the list of recent funding rounds of Reverie Labs:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 03, 2021 | 7708004 | Series A | 7125014 | 3676575 | 5648661 | 2172184 |
2017 | 3565 | Seed | 9587 | 7694 | 1250 |
Access funding benchmarks and valuations. Sign up today!View details of Reverie Labs's funding rounds and investors
Reverie Labs' founders and board of directors
Founder? Claim ProfileThe founders of Reverie Labs are Jonah Kallenbach and Ankit Gupta. Jonah Kallenbach is the CEO of Reverie Labs.
Here are the details of Reverie Labs' key team members:
- Jonah Kallenbach: Co-Founder & CEO of Reverie Labs.
- Ankit Gupta: Co-Founder & CTO of Reverie Labs.
View details of Reverie Labs's Founder profiles and Board Members
Reverie Labs' employee count trend
Reverie Labs has 27 employees as of Dec 22. Here is Reverie Labs's employee count trend over the years:
Uncover Reverie Labs' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Reverie Labs's Competitors and alternates
Top competitors of Reverie Labs include Recursion Pharmaceuticals, XtalPi and Schrodinger. Here is the list of Top 10 competitors of Reverie Labs, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Recursion Pharmaceuticals 2013, New York (United States), Public | AI-enabled drug discovery and development platform for novel therapeutics | $452M | 72/100 | |
2nd |  XtalPi 2014, Cambridge (United States), Public | AI-based drug research and development company | $785M | 67/100 | |
3rd |  Schrodinger 1990, New York City (United States), Acquired | Provider of a web-based simulation and modelling tool | $162M | 66/100 | |
4th |  Healx 2014, Cambridge (United Kingdom), Series C | AI-powered drug discovery platform to treat rare diseases | $115M | 64/100 | |
5th |  METiS Therapeutics 2017, Cambridge (United States), Series B | Provider of an AI-assisted platform for drug discovery and development | $252M | 63/100 | |
6th |  Xaira 2023, San Francisco (United States), Series D | AI-enabled platform for drug discovery and development | $1B | 63/100 | |
7th |  Valo Health 2019, Boston (United States), Series B | AI-powered platform for drug discovery and development | $450M | 62/100 | |
8th | Provider of an AI and quantum physics to discover therapeutic molecules | $103M | 62/100 | ||
9th |  In Silico 2014, Cambridge (United States), Public | AI-enabled bioinformatics platform for drug discovery and biomarker development | $510M | 62/100 | |
10th |  Isomorphic Labs 2021, London (United Kingdom), Series D | AI-driven platform to accelerate drug discovery process | $600M | 62/100 | |
29th | Reverie Labs 2017, Boston (United States), Acquired | Provider of an AI based molecular modelling and optimization software for research & development | $32M | 50/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Reverie Labs's competitors? Click here to see the top ones
Reverie Labs's Investments and acquisitions
Reverie Labs has made no investments or acquisitions yet.
News related to Reverie Labs
•
•
Ginkgo Bioworks acquires 3 companiesLabPulse.com•Mar 01, 2024•Ginkgo Bioworks, Proof Diagnostics, Reverie Labs, Patch
•
•
•
•
Reverie Labs raises $25 million for its AI drug discovery platformVentureBeat•Feb 03, 2021•Reverie Labs
•
Reverie Labs uses new machine learning algorithms to fix drug development bottlenecksTechCrunch+•Mar 16, 2018•Reverie Labs
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Reverie Labs
Explore our recently published companies
